Senetek PLC Announces Riley-Nacht LLC - Leading Global Brand Development Company...

Senetek PLC Announces Riley-Nacht LLC - Leading Global Brand Development
Company to Direct Dermatological Product Marketing Program

NAPA, Calif., April 17 /PRNewswire-FirstCall/ -- Senetek PLC
(OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the
development of technologies that target the science of healthy aging, today
announced it has engaged Riley-Nacht LLC, a global brand development and
marketing company focused on the skincare industry to support the
commercialization of Senetek's dermatological products.
Riley-Nacht was founded by Les Riley, Dr. Sergio Nacht and Brian Riley.
Riley-Nacht is known for their expertise in all phases of brand development
and will play a key role in Senetek's dermatological product marketing
program.
Les Riley stated, "Pyratine-6(TM) is a next generation skin care
technology. Based on a review of the clinical data, we are enthusiastic about
working with Senetek on its commercial development. Pyratine-6(TM) has the
potential for extraordinary success in the global skin care markets."
Les Riley has over thirty years of experience in the pharmaceutical and
skincare industries. Prior to founding Riley-Nacht, Mr. Riley was President of
Cardinal Health, Topical Technologies, a company formed through the
acquisition of Advanced Polymer Systems that integrated existing Cardinal
Health technologies and infrastructure. Mr. Riley has also served as
President and CEO of TriStrata Incorporated, and President and CEO of
NeoStrata Company Inc., a subsidiary of TriStrata. Mr. Riley spent seventeen
years with Johnson & Johnson Co., Inc. as President of the Dermatological
Division, where he was responsible for operations, including sales and
marketing, licensing and acquisitions, and new product development.
Mr. Riley was granted membership in the American Academy of Dermatology in
2004, in recognition of his years of service and contribution to advancing the
specialty of dermatology.
Dr. Sergio Nacht is a skin biologist with 35 years of academic, industrial
and commercial experience. Prior to the founding of Riley-Nacht, Dr. Sergio
Nacht was Senior Vice President of Dermatology and Skin Care at Cardinal
Health, Topical Technologies, where he was responsible for the overall
expansion of Topical Technologies with emphasis on dermatological and skincare
technologies and for technical business development worldwide. Dr. Nacht also
occupied key scientific and R&D positions at Richardson-Vicks/ Procter &
Gamble and at Alza Corporation.
Dr. Nacht is a member of several professional societies, including the
American Academy of Dermatology, The Dermatology Foundation and The Society of
Cosmetic Chemists. He has co-authored more than 50 scientific papers and book
chapters and holds fifteen U.S. patents.
Brian Riley has over ten years experience in the sales, marketing and
distribution of skin and personal health products. Mr. Riley created and
developed Boulder Consulting, a marketing firm focused on business planning,
marketing, and product development for clients in the skincare industry
including Boston University, Department of Dermatology, and Rejuvenation
Centers, Ltd.
Prior to founding Boulder Consulting, Mr. Riley partnered with leading
executives in the industry to form DermFirst Inc., with clients including
Ortho-Neutrogena, Allergan Skincare, ICN Pharmaceuticals, ProCyte, Inc.,
Genesis Pharmaceutical, and NeoStrata Company. Mr. Riley was also involved in
the development of an anti-aging treatment system marketed through direct
response television.
As a marketer, Mr. Riley had responsibility at Medicis Pharmaceutical
Corporation for the launch and overall management of TxSystems, a new business
unit specializing in non-prescription dermatologicals for improving the
appearance of aging skin. Mr. Riley was also involved in the launch and/or
marketing of the Medicis prescription and OTC products, including Lustra(R),
Esoterica(R), Dynacin(R), Triaz(R), Novacet(R), Loprox(R), Lidex(R), and
Synalar(R).
Frank Massino, Chairman and Chief Executive Officer of Senetek stated,
"The team of Riley and Nacht bring unparalleled expertise to our program for
the accelerated development of Senetek's substantial dermatological portfolio.
Their extensive networks and affiliations with current thought leaders in
dermatology will help define the course of our marketing efforts in this
area."
About Senetek PLC
Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the
development of breakthrough technologies that target the science of healthy
aging. The Company's extensive research collaborations have resulted in a
strong pipeline of patented compounds and products with broad therapeutic
applications and a leading presence in dermatology. Senetek collaborates with
established specialty pharmaceutical companies in the final development and
marketing of its proprietary products, most recently resulting in the
development of the best-selling anti-aging product sold in the North American
physician market.
For more information, visit the company's website at
http://www.senetekplc.com.
This news release contains statements that may be considered
'forward-looking statements' within the meaning of the Private Securities
Litigation Reform Act. Forward-looking statements by their nature involve
substantial uncertainty, and actual results may differ materially from those
that might be suggested by such statements. Important factors identified by
the Company that it believes could result in such material differences are
described in the Company's Annual Report on Form 10-K for the year 2007.
However, the Company necessarily can give no assurance that it has identified
or will identify all of the factors that may result in any particular
forward-looking statement materially differing from actual results, and the
Company assumes no obligation to correct or update any forward-looking
statements which may prove to be inaccurate, whether as a result of new
information, future events or otherwise.
SOURCE Senetek PLC

Marjorie Hays, Vice President, Communications of Senetek PLC, +1-707-226-3900,
ext. 102